How Gene Therapy Works—and Why It's Changing Medicine

What Is Gene Therapy?

At its most fundamental, gene therapy is medicine at the level of DNA. Rather than treating symptoms with drugs or surgery, gene therapy targets the genetic root cause of disease — adding, silencing, or rewriting the faulty instructions inside a patient's own cells. After decades of setbacks and cautious breakthroughs, it is now delivering real, lasting cures for conditions that were once considered untreatable.

How Faulty Genes Cause Disease

Every cell in the human body runs on instructions encoded in DNA. Genes are the segments of that code that tell cells how to build proteins — the molecular machines that govern everything from blood clotting to vision to muscle function. When a gene is mutated or missing, the protein it encodes may malfunction or disappear entirely. The result can range from rare inherited conditions such as spinal muscular atrophy (SMA) to common diseases with significant genetic components. Gene therapy aims to fix — or work around — those broken instructions at their source.

The Delivery Problem: Vectors

The central engineering challenge in gene therapy is getting the right genetic material into the right cells. Scientists use molecular delivery vehicles called vectors. Most approved therapies use modified viruses, which have evolved over millions of years to be expert at entering human cells and depositing genetic cargo — with all disease-causing elements stripped out.

Two types dominate the field:

• Adeno-associated viruses (AAVs) are small, non-pathogenic, and ideal for reaching the liver, eye, brain, and heart. The FDA-approved Zolgensma for spinal muscular atrophy uses an AAV to deliver a working copy of the SMN1 gene in a single intravenous infusion.
• Lentiviral vectors, derived from a disabled form of HIV, carry larger genetic payloads and integrate permanently into the cell's genome. They are commonly used in therapies that modify a patient's blood stem cells outside the body before reinfusion.

Researchers are also developing non-viral delivery systems — including lipid nanoparticles, the same technology used in mRNA vaccines — to bypass immune reactions that can limit repeated dosing with viral vectors.

Two Strategies: In Vivo and Ex Vivo

In vivo therapy delivers the vector directly into the patient's body — injected into the bloodstream, eye, or muscle — where it travels to target tissue and deposits the therapeutic gene without cells ever leaving the body. Ex vivo therapy removes the patient's own cells, modifies them in the laboratory, then infuses them back. This approach allows more precise editing and quality control, and underpins treatments for blood disorders such as sickle cell disease.

The FDA-approved Casgevy, authorized in late 2023, uses CRISPR gene editing to silence a gene that suppresses fetal hemoglobin — effectively giving sickle cell patients a functional replacement protein without transplanting donor cells.

What Gene Therapy Can Already Treat

As of 2026, more than 37 cell and gene therapy products carry FDA approval. Notable examples include Luxturna for inherited blindness caused by RPE65 mutations, Zolgensma for SMA, Casgevy and Lyfgenia for sickle cell disease, and Elevidys for Duchenne muscular dystrophy. Active clinical trials are underway for hemophilia, certain cancers, Huntington's disease, and inherited deafness, according to the National Institutes of Health.

The Steep Cost and Access Gap

Gene therapy's biggest obstacle today is not scientific — it is economic. These treatments rank among the most expensive medicines ever made. Hemgenix, a therapy for hemophilia B, carries a list price of $3.5 million per patient. Casgevy costs around $2.2 million. Manufacturing is labor-intensive, patient populations are tiny, and companies must recoup enormous research investments. As NPR reported in 2026, both cost and geography — these treatments are only available at specialized academic medical centers — leave many eligible patients without access.

Regulators are trying to adapt. In early 2026, the FDA unveiled an accelerated approval pathway for individualized therapies targeting ultra-rare diseases, inspired partly by the case of an infant treated with a bespoke gene-editing therapy designed for his unique genetic mutation — the first therapy ever custom-built for a single patient.

What Comes Next

Gene therapy remains a young field — the first US-approved treatment, Luxturna, arrived only in 2017. Yet the pace of innovation is accelerating. Scientists are improving vector precision, developing in vivo CRISPR delivery that edits genes without removing any cells, and working on ways to make manufacturing cheaper and more scalable. For diseases that once had no cure, gene therapy is increasingly offering one — and the scientific foundations are stronger than ever.